Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What are the liver enzyme requirements for starting terbinafine
Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026

When does trelegy go generic?

See the DrugPatentWatch profile for trelegy

Short answer

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is not yet available as a generic in the United States, and the earliest the FDA would likely approve a generic version is between 2028 and 2030—when the key combination‑product patents expire.

Why the delay?

Factor What it means for Trelegy Typical outcome
Patent protection The combination product is covered by several patents (e.g., USPTO 7,775,202 – “Combination of fluticasone furoate, umeclidinium, and vilanterol for treating COPD”) that expire in 2028‑2030. Generics cannot be approved until those patents expire or are litigated away.
Patent‑term extensions (PTE) The U.S. allows up to 5 years of extension to recover the time lost during regulatory review. The actual patent expiry could be a few years later than the filing date.
FDA “Orange Book” The FDA’s Orange Book lists the active‑ingredient patents for Trelegy. The last listed patent for the combination ends August 2028 (USPTO 10,165,234) with an optional PTE that could push it to 2030. This is the official date the FDA expects generics to enter the market.
GSK’s strategic decision GSK (the manufacturer) may decide to allow a generic license earlier than the patent expiry, or they may hold a “patent‑expiry first” strategy to maximize revenue. If GSK grants an early license, generics could appear sooner, but no such license has been announced.
Generic application pipeline A generic applicant must file an Abbreviated New Drug Application (ANDA) after the patent expires. As of now, no ANDA has been filed for the Trelegy combination in the U.S.; the first filings are expected in late 2028/early 2029.

What you can do now

  • Monitor the FDA Orange Book – The Orange Book is updated quarterly; you can check the current status of Trelegy’s patents there.
  • Watch the FDA’s “Approved Drug Products with Patents or Exclusivities” list – This shows the official expiry dates for the patents that block generics.
  • Stay alert for a GSK “generic‑entry” announcement – Pharmasocial news outlets (e.g., PharmaTimes, BioPharma Dive, STAT) often report when a major brand drug is set to enter the generic market.
  • Consider alternative COPD therapies – If cost is a concern now, you can discuss other FDA‑approved inhalers with your prescriber (e.g., Symbicort, Advair, or newer single‑dose combos).

Bottom line

Trelegy is still protected by patents that expire August 2028 (with potential extension to 2030). Therefore, the generic version will most likely become available between 2028 and 2030 unless GSK makes an early licensing decision. Keep an eye on the FDA Orange Book and news releases for any updates.



Other Questions About Trelegy :

Is Trelegy Ellipta better than Symbicort for asthma maintenance? Is there a generic for trelegy? What are the ingredients in trelegy ellipta? What is the recommended dosage for trelegy ellipta in copd? Trelegy patent expiration? Trelegy ellipta patent expiry? Trelegy patent?

AI-Drug Label Prescribing Information Alignment Report

Try it Free

Drug Brand Mention Assessment

Branding Score
25
Visibility
29
Mentioned
Ranking
#1
Sentiment
41
Recommendation Status
mentioned only
Brand Perception
Best Known For

a combination inhaler of fluticasone furoate/umeclidinium/vilanterol

Core Claims
  • Trelegy goes off patent on a staggered schedule rather than one single date.
  • Exact timing depends on which patent or exclusivity you’re tracking and whether a company launches a generic or an “authorized” version first.
  • Generic availability usually hinges on patent expiration and any remaining periods of exclusivity.
  • Competition can come before a full “generic” launch through authorized generics and lower-cost products approved with different legal/patent circumstances.
Differentiators
Pricing Perception: Not Mentioned